We would love to hear your thoughts about our site and services, please take our survey here.
DD77 : Research notes can be found here -
https://www.ondoplc.com/investors/advisors-2/
Hi Wyn , actually in paper profit still a bit to go to reach my target ( as you like to talk about the SP my SP target now £5) - would like to think AVCT onwards /upwards from here, anyway think company in better shape today than when i first invested years ago , so exciting times ahead .
I am 77.5 years old . Cash in next 2 years or before , so hopefully around for a bit longer , be nice to see LTH shareholders get their rewards .
Do wish Avacta success & deliver " transform treatment outcomes for cancer patients."
P.S, beinthelead : Good for you !!
No problem beinthelead - i like to wind you up - for a smart guy you are not so clever - i have never been a member of the telegram group & no intention of joining . I am interested in all Avacta assets and expect to get a good return on my investment will take as long as it takes . I trust the Avacta team & like the CEO .
I make up my own mind , my money ,my decision . You on the other hand probably overstretched and perhaps had expectations for a an earlier payout , sorry not yet delivered- who knows only you - why would anyone knock their own investment .
We all endure , just a message board , .
Note Eliot Forster started his new CEO job : "His appointment strengthens the Levicept leadership team as the company matures from a tightly clinical development-focused phase towards future advancement and ultimate commercialisation of LEVI-04." Hopefully EF will remain Avacta Chairman .
Anyway Dr Smith in safe hands as can always call on /rely /read @ beinthelead et al very positive posts help keep him on the right track .
---------------------------------
Eliot ForsterEliot Forster
• 3rd+ • 3rd+
Biotech ExecutiveBiotech Executive
5d • 5d •
Follow
Absolutely delighted to join Simon and the Levicept team at this important time for the business! Very cool!!
LEVICEPT LTDLEVICEPT LTD
198 followers198 followers
5d • 5d •
Follow
We thrilled to announce that Eliot Forster has joined us as CEO, with our founder and inventor of LEVI-04, Simon Westbrook focusing on our clinical programme and science as CSO.
Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, including at NASDAQ-listed biotechs F-star, an invoX company and Immunocore, and at big pharmas. His appointment strengthens the Levicept leadership team as the company matures from a tightly clinical development-focused phase towards future advancement and ultimate commercialisation of LEVI-04.
LEVI-04, a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc) that modulates the #neurotrophin pathway, is in a 500+ patient phase II clinical trial, as a once-a-month injectable for the treatment of osteoarthritis and chronic pain."
FYI Upgraded product from LD manufacturer Meridian Bioscience - Whilst LD currently still a commercial asset for Avacta nice to see them having new improved products to sell .
-----------------
https://www.linkedin.com/company/launch-diagnostics-france-sas/
Launch Diagnostics France SASLaunch Diagnostics France SAS
"Rate this translation
According to the alert of the Directorate-General for Health (DGS) of November 29, 2023: "The health authorities have been informed of an unusual upsurge in cases of Mycoplasma pneumoniae respiratory infections, including cases requiring hospitalization in adults and children in France."
The DGS recommends the diagnosis of Mycoplasma pneumoniae by molecular biology.
The Alethia™ Mycoplasma Direct DNA Amplification Test is a qualitative in vitro diagnostic assay for the direct detection of Mycoplasma pneumoniae DNA in human pharyngeal specimens obtained from patients suspected of having Mycoplasma pneumoniae infection.
https://www.launchdiagnostics.com/product/alethia-lamp-based-molecular-solution-from-meridian-bioscience/
https://www.meridianbioscience.com/diagnostics/disease-areas/respiratory/mycoplasma/alethia-mycoplasma-direct/
hi nursesteve did find this link for telegram group if that helps ;
---------------
become a better investor
@albertmay59
if you are an avacta investor or thinking of being one #avct, telegram's chat group & info channel has just posted a must read "how much more effective is ava6000 than doxorubicin". if not already subscribe at
****
join group chat on telegram
become a better investor
@albertmay59
if not already subscribe at
****
join group chat on telegram
*************+tf3wtkmgzcg1yzrk
https://twitter.com/albertmay59/status/1625077521367564288
Spot the difference : ( courtesy of dave twitter )
Was : " Avacta Group plc (AIM: AVCT), a life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics,
Now : " Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, "
Focused : directing a great deal of attention, interest, or activity towards a particular aim:
Developing Drug development – covering the steps taken to convert the molecule above into an approved and registered drug product
-------------------
Next stage : Commercialisation – which includes all the steps taken to convert the product into an approved therapeutic, launch into the market and to generate sales
AffyXell Not listed as speakers but listed "Snapshot of Attending Companies" anyway hopefully making progress since last Avacta update .
"Mark your calendars for the much-awaited 𝑪𝒆𝒍𝒍 𝑻𝒉𝒆𝒓𝒂𝒑𝒚 𝒇𝒐𝒓 𝑨𝒖𝒕𝒐𝒊𝒎𝒎𝒖𝒏𝒆 𝑫𝒊𝒔𝒆𝒂𝒔𝒆 𝑺𝒖𝒎𝒎𝒊𝒕, taking place in Philadelphia from November 28th to 30th. "
Snapshot of Attending Companies
https://info.hansonwade.com/Cell_Therapy_for_Autoimmune_Disease_Summit_Brochure
(Avacta’s JV AffyXell is progressing AFX001 through IND enabling studies, with Phase 1 planned for 2024. AffyXell and Avacta presented new data at the International Society for Cell Therapy Conference in Paris in May .)
http://affyxell.com/pipeline/pipeline.php
Interesting "The net proceeds of the Placing are estimated to be approximately £1.0 million."
Well below £5.0 million ?
"The Company is proposing to raise gross proceeds of approximately £5.0 million through the proposed placing of the Placing Shares at the Placing Price to investors using the it's existing share authorities to issue shares for cash on a non-pre-emptive basis. "
Neat : FlashDx’s Respiratory Panel
https://www.goffinmoleculartechnologies.com/product/flashdx-respiratory-panel-1-0/
https://www.linkedin.com/feed/update/urn:li:activity:7134896759503228928/
"France is facing a real outbreak of pneumonia among children, according to data from #SantépubliqueFrance. (+38% of pneumonitis procedures in the emergency room for children under 15 years old in one week according to the OSCOUR bulletin).
Launch Diagnostics France SAS has a molecular biology solution for the detection of Mycoplasma pneumoniae.
• Single cassette
• Technical time less than 1 minute
• Result in less than an hour
#FlashDx #santépubliquefrance #pneumopathie #mycoplasmapneumoniae
In addition to comprehensive data package. I am looking forward to seeing RNS that a first patient has been dosed in this short study , especially " as a first line treatment in patients " which would be a great endorsement for pre|CISIONTM technology.
----------- " the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA) " - assume FDA have no issues .
-----------------
We have been told it works :
Discover pre|CISIONTM technology – delivering tumour microenvironment-targeted cancer therapies
https://avacta.com/therapeutics/
"20 Oct 2023
International Conference on Molecular Targets and Cancer Therapeutics, overview
By Fiona McLaughlin
"pre|CISIONTM is a tumour microenvironment targeting platform aimed at delivering potent warheads directly to the tumour, reducing systemic exposure and toxicity and thereby dramatically improving tolerability to enhance efficacy of the treatment. This targeted approach to delivering cancer treatments is now clinically validated by our lead molecule AVA6000. In an ongoing Phase 1a trial, AVA6000 shows not only a strong safety profile, but concentrates the doxorubicin warhead in the tumour."
"Never say Never " on affimers commercialisation however below is the only show in town at the moment for Avacta & impatient SP punters who ridicule the CEO .
CEO - "Thanks for listening. I hope that's been helpful, and I look forward to our planned detailed data release for AVA6000 later in Q4. "
Https://www.linkedin.com/feed/update/urn:li:activity:7133764119358246914/
"Launch Diagnostics Limited
1,329 followers
1d
All ready to go at #UKNEQAS For Microbiology User Day!
Today we’ll be talking about our latest CLIA platform for serology diagnostics, the VirClia Lotus, capable of testing over 90 parameters using a monotest format that reduces on waste.
We’ll also be showcasing our antimicrobial susceptibility testing and molecular portfolio.
Please visit us at our stand for all your microbiology diagnostic solutions!
#ukneqas #eqa #conference #scientificinnovation #microbiology #diagnostics #antimicrobialresistance #antimicrobialstewardship #biomedicalscience #biomedicalscientist #patientcare #nhs
Southern Water about to start a trial - 1000 LeakBots for 12 months - collecting data etc , interesting discussion .
apparently Win/Win for water boards & customers .
FYI https://www.ccw.org.uk/podcasts/
Also Fiona Mcl page 22
https://7915828.fs1.hubspotusercontent-na1.net/hubfs/7915828/DDW%20Immunotherapy%20eBook%2010%202023.pdf
Good Morning Think same article posted previously anyway Avacta included again in latest DDD eBOOK version if you missed it first time .
( page 14 onwards )
https://7915828.fs1.hubspotusercontent-na1.net/hubfs/7915828/DDW%20Immunotherapy%20eBook%2010%202023.pdf
"Learning outcomes:
"Advances in cancer care: Where are the advances in treatments for triple-negative breast cancer?
Drug development: 5 years of oncology developments
Why immunotherapy is here to stay
Precision cancer therapies: Where are we?"
CEO interview
FYI https://www.ccw.org.uk/podcasts/